Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-17

FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZARXIO (filgrastim-sndz) filed by Sandoz Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZARXIO (FILGRASTIM-SNDZ)

Snippet

SUPPL AP for ZARXIO (FILGRASTIM-SNDZ)